Corona Remedies (NSE:CORONA) Other Stockholders Equity: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CORONA Corona Remedies Ltd NSE:CORONA
18 GF Score
Price ₹2,137.10
! 4 Warning Signs
View Full Analysis

What is Corona Remedies Other Stockholders Equity?

Corona Remedies NSE:CORONA +1.13% 18 Other Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Corona Remedies's Other Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

Corona Remedies Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Corona Remedies's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies Other Stockholders Equity Chart

Corona Remedies Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
-0.00 0.00 0.00 0.00

Corona Remedies Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:CORONA
18GF Score
Corona Remedies Ltd NSE:CORONA
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corona Remedies Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹0 Mil mean?
Corona Remedies (NSE:CORONA) has a Other Stockholders Equity of ₹0 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Corona Remedies and its competitors.
Is Corona Remedies' Other Stockholders Equity too high?
Corona Remedies' current Other Stockholders Equity is ₹0 Mil. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Other Stockholders Equity compare to LLY and JNJ?
Corona Remedies' Other Stockholders Equity of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Corona Remedies and its competitors. Corona Remedies's current Other Stockholders Equity is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Other Stockholders Equity of ₹0 Mil. The current Other Stockholders Equity is ₹0 Mil. Corona Remedies' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Other Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corona Remedies Business Description

Other Exchanges 544644:India
Address S. G. Highway, CORONA House, C - Mondeal Business Park, Near Gurudwara, Thaltej, Ahmedabad, GJ, IND, 380 059
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score

Get the complete analysis for NSE:CORONA

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,137.10
Price